Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone

NCT04676646 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

366

Enrollment

INDUSTRY

Sponsor class

Conditions

Hyperkalaemia
Heart Failure With Reduced Ejection Fraction

Interventions

DRUG: Sodium zirconium cyclosilicate
DRUG: Placebo
OTHER: Spironolactone

Sponsor

AstraZeneca